

Friday, March 28, 2025

Time	Title	Speaker
8:00 AM	BREAKFAST AND REGISTRATION	
9:00 AM	Introduction from conference organizers	
9:05 AM	Opening remarks	Michael Teitell, MD, PhD <i>University of California, Los Angeles</i>
	PSMA imaging session 1	
9:10 AM	History of PSMA	Martin Pomper, MD, PhD <i>University of Texas, Southwestern</i>
9:20 AM	Landscape of approved PSMA imaging agents: does it matter?	Amir Iravani, MD <i>University of Washington</i>
9:30 AM	Pictorial Atlas of PSMA PET	Matthias Benz, MD <i>University of California, Los Angeles</i>
9:40 AM	Impact of clinical guidelines on the utilization of PSMA PET	Emmanuel Antonarakis, MD <i>University of Minnesota</i>
9:50 AM	<i>Panel discussion</i>	
	PSMA imaging session 2	
10:00 AM	The changing role of MRI in staging patients with prostate cancer	Steven Raman, MD <i>University of California, Los Angeles</i>
10:10 AM	PRIMARY score and where it plays a role	Michael Hofman, FRACP, MBBS <i>Peter MacCallum Cancer Centre, Melbourne, Australia</i>
10:20 AM	PSMA PET fusion guided biopsy	Wayne Brisbane, MD <i>University of California, Los Angeles</i>
10:30 AM	Role of PSMA PET in surgical planning and post-operative management	Carissa Chu, MD <i>University of California, San Francisco</i>
10:40 AM	<i>Panel discussion</i>	
10:50 AM	COFFEE BREAK	
	PSMA imaging session 3	
11:00 AM	Development of upcoming and promising new PSMA imaging agents	Wolfgang Fendler, MD <i>University Hospital Essen, Germany</i>
11:10 AM	WB PSMA quantitative parameters: why are we not using WB PSMA PET parameters in the real world	Irene Buvat, PhD <i>Institut Curie, Orsay, France</i>
11:20 AM	<i>Panel discussion</i>	
	PSMA imaging session 4	
11:30 AM	Who benefits from oligo-metastases directed therapy?	Julian Hong, MD, MS <i>University of California, San Francisco</i>
11:40 AM	Can we kill the bone scan?	Daniel Spratt, MD <i>University Hospitals, Cleveland, OH</i>
11:50 AM	How to crush a PSMA PET report: guidelines and scoring systems	Phillip Kuo, MD, PhD <i>City of Hope, Los Angeles</i>
12:00 PM	Incorporating PSMA PET into trial endpoints. PCWG4 updates	Michael Morris, MD <i>Memorial Sloan Kettering, New York</i>
12:10 PM	Panel discussion + mini tumor board 1 [PET imaging]	

Friday, March 28, 2025 continued

Time	Title	Speaker
12:40 PM	LUNCH BREAK	
	LuPSMA therapy session 1	
1:25 PM	Path to Clinical Use: Lesson from compassionate use in Germany	Wolfgang Fendler, MD <i>University Hospital Essen, Germany</i>
1:35 PM	Post-VISION: Real world experience in the US, how is PSMA RLT being used?	Matthew Rettig, MD <i>University of California, Los Angeles</i>
1:45 PM	Radiation Safety and Ecology: Comparison of practices across the US and the world	Catherine Meyer, PhD <i>University of California, Los Angeles</i>
1:55 PM	<i>Panel discussion</i>	
	LuPSMA therapy session 2	
2:05 PM	How are we getting paid Theranostics?	Denise Merlino, CPC, MBA, CNMT <i>Merlino Healthcare Consulting, Florida</i>
2:15 PM	PSMA RLT in a Medical Oncology private center	Luke Nordquist, MD <i>Xcancer, Omaha, NE</i>
2:25 PM	PSMA RLT in a Radiation Oncology private center	Dustin Boothe, MD <i>Intermountain Health, Salt Lake City, UT</i>
2:35 PM	Patient Experience	TBD
2:45 PM	<i>Panel discussion</i>	
	LuPSMA therapy session 3	
2:55 PM	Pre-chemo trials: PSMAfore/SPLASH/ECLIPSE	Emmanuel Antonarakis, MD <i>University of Minnesota</i>
3:05 PM	Moving into the castration sensitive setting	Michael Morris, MD <i>Memorial Sloan Kettering Cancer Center</i>
3:15 PM	PSMA RLT for oligometastatic disease	Amar Kishan, MD <i>University of California, Los Angeles</i>
3:25 PM	Overview of enrolling Phase 2/3 trials	Jeremie Calais, MD, PhD <i>University of California, Los Angeles</i>
3:35 PM	<i>Panel discussion</i>	
3:45 PM	COFFEE BREAK	
	LuPSMA therapy session 4	
3:55 PM	When should we use FDG PET?	Andrei Iagaru, MD <i>Stanford University, California</i>
4:05 PM	What's the best way to evaluate response: SPECT vs PSMA PET?	Thomas Hope, MD <i>University of California, San Francisco</i>
4:15 PM	Moving beyond 6x6	Matthias Eiber, MD, PhD <i>Technische Universität München, Germany</i>
4:25 PM	Treatment Sequencing	Tanya Barauskas Dorff, MD <i>City of Hope, Los Angeles</i>
4:35 PM	Panel discussion + mini tumor board 2 [PSMA RLT]	
5:25 PM	Wrap up for the day	
5:30 PM	Poster power pitches	
5:45 PM	Poster session reception	
6:30 PM	Poster awards	



Saturday, March 29, 2025

Time	Title	Speaker
8:00 AM	BREAKFAST	
	Dosimetry Session 1	
9:00 AM	Are we underdosing?	Amir Iravani, MD <i>University of Washington</i>
9:10 AM	Lessons from radiation oncology: How can we improve PSMA RLT?	Daniel Spratt, MD <i>University Hospitals, Cleveland, OH</i>
9:20 AM	"Beyond the 23 Gray threshold"	Ana Ponce Kiess, MD, PhD <i>Johns Hopkins University, Baltimore, MD</i>
9:30 AM	How to use quantitative dosimetry and act on it to adapt treatment	Carlos Uribe, PhD, MCCPM <i>BC Cancer, University of British Columbia</i>
9:40 AM	AI for Dosimetry	Irene Buvat, PhD <i>Institut Curie, Orsay, France</i>
9:50 AM	Let's get paid for Dosimetry	Denise Merlino, CPC, MBA, CNMT <i>Merlino Healthcare Consulting, Florida</i>
10:00 AM	<i>Panel discussion</i>	
	Antibody and other Ligands Session	
10:10 AM	PSMA-I&T vs PSMA-617: is there a difference	Matthias Eiber, MD, PhD <i>Technische Universität München, Germany</i>
10:20 AM	Role of PSMA targeted antibodies	Scott Tagawa, MD, MS <i>Weill Cornell Medicine, New York</i>
10:30 AM	Next generation PSMA radioligands	Martin Pomper, MD, PhD <i>University of Texas, Southwestern</i>
10:40 AM	<i>Panel discussion</i>	
10:50 AM	COFFEE BREAK	
	Alpha and Other Radionuclides Session	
11:00 AM	How PSMA RLT kills the cells? Alpha vs beta radiobiology	Ana Ponce Kiess, MD, PhD <i>Johns Hopkins University, Baltimore, MD</i>
11:10 AM	Ac225 PSMA experience	Alfred Morgenstern, PhD <i>Joint Research Centre, Karlsruhe, Germany</i>
11:20 AM	Management of dry mouth	Sue Yom, MD, PhD <i>University of California, San Francisco</i>
11:30 AM	Pb212 PSMA vs Ac225 PSMA: from biology to supply	Alfred Morgenstern, PhD <i>Joint Research Centre, Karlsruhe, Germany</i>
11:40 AM	Role for other radionuclides: Tb161	Michael Hofman, FRACP, MBBS <i>Peter MacCallum Cancer Centre, Australia</i>
11:50 AM	<i>Panel discussion</i>	
	PSMA-targeted Non-RPT Session	
12:00 PM	CAR-T and Bispecific Antibodies targeting PSMA	Tanya Barauskas Dorff, MD <i>City of Hope, Los Angeles</i>
12:10 PM	Role of ADCs in prostate cancer	John Shen, MD <i>University of California, Los Angeles</i>

Saturday, March 29, 2025 continued

Time	Title	Speaker
1:40 PM	Value of animal models in evaluating RLT	Tanya Stoyanova, PhD <i>University of California, Los Angeles</i>
12:20 PM	<i>Panel discussion</i>	Tanya Barauskas Dorff, MD Matthew Rettig, MD John Shen, MD Tanya Stoyanova, PhD Scott Tagawa, MD, MS
12:30 PM	LUNCH BREAK	
	Keynote lecture	
1:30 PM	Improving outcomes with combination therapy	Michael Hofman, FRACP, MBBS <i>Peter MacCallum Cancer Centre, Australia</i>
1:50 PM	<i>Panel discussion</i>	
	New Developments in GU Radioligand Therapy	
2:00 PM	GRPR and other peptides for targeting prostate cancer	Andrei Iagaru, MD <i>Stanford University, California</i>
2:10 PM	DLL3, CD46, STEAP1 and others	Robert Flavell, MD, PhD <i>University of California, San Francisco</i>
2:20 PM	HK2 and HK3 experience	David Ulmert, MD <i>University of California, Los Angeles</i>
2:30 PM	CA-IX in renal cell cancer	Brian Shuch, MD <i>University of California, Los Angeles</i>
2:40 PM	Opportunity for RLT in bladder cancer	Vadim Koshkin, MD <i>University of California, San Francisco</i>
2:50 PM	<i>Panel discussion</i>	
3:00 PM	Closing comments	